Anselmo Garcia, MD
Pulmonary Disease · Phoenix, AZNPI 1679791248
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,609 of the $5,581 with a category attached, or 82.6%. It is spread thinly across 40 manufacturers, the largest accounting for just 20.4% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,867, 2.4 times the $782 reported in 2019.
Across 229 payments — averaging $24.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$1K
- AstraZeneca$513
- GSK$359
- Boehringer Ingelheim$346
- Sanofi$343
- Merck$313
- plus $3K from 34 others
What the payments were for
- Travel & lodging$84215%
- Food & beverage$4,60983%
- Education$1302%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 11 | $1,139 |
| AstraZeneca | 16 | $513 |
| GSK | 19 | $359 |
| Boehringer Ingelheim | 16 | $346 |
| Sanofi | 17 | $343 |
| Merck | 11 | $313 |
| Regeneron Healthcare Solutions, Inc. | 10 | $272 |
| Actelion Pharmaceuticals US, Inc. | 6 | $252 |
| Pulmonx Corporation | 11 | $226 |
| Electromed, Inc. | 18 | $220 |
| Baxter Healthcare | 8 | $151 |
| Insmed, Inc. | 7 | $143 |
| Genentech USA, Inc. | 10 | $138 |
| Sunovion Pharmaceuticals Inc. | 15 | $137 |
| Mylan Specialty L.p. | 15 | $133 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $117 |
| ANI Pharmaceuticals, Inc. | 3 | $82 |
| Verona Pharma, Inc. | 1 | $69 |
| Sanofi-aventis U.S. LLC | 1 | $68 |
| Viatris Specialty LLC | 3 | $59 |
| Grifols USA, LLC | 2 | $54 |
| Harmony Biosciences LLC | 2 | $51 |
| Pfizer | 2 | $42 |
| Advanced Respiratory, Inc | 3 | $38 |
| Philips North America LLC | 2 | $35 |
| Novartis | 1 | $29 |
| Inogen, Inc. | 1 | $25 |
| Bayer | 1 | $23 |
| Inspire Medical Systems, Inc. | 1 | $22 |
| Vifor Pharma, Inc. | 1 | $22 |
| Biogen | 1 | $20 |
| Johnson & Johnson | 1 | $18 |
| Jazz Pharmaceuticals Inc. | 1 | $17 |
| Phadia US Inc. | 1 | $17 |
| Olympus America Inc. | 1 | $17 |
| Lilly USA, LLC | 1 | $17 |
| Amgen | 1 | $15 |
| Gilead | 1 | $15 |
| Siemens Medical Solutions USA, Inc. | 1 | $13 |
| Shire North American Group Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,581 in reported general payments places this provider in the 65th percentile of 250 pulmonary disease providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 17 | $77,121 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 24 | $16,226 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 14 | $8,920 |
| SymbicortBudesonide/Formoterol Fumarate | 17 | $4,029 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 63 | $1,747 |
| Fluconazole | 13 | $614 |
| Doxycycline Hyclate | 16 | $173 |
| Methylprednisolone | 16 | $131 |
| Levofloxacin | 13 | $68 |
| Prednisone | 20 | $44 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta | $359 | $16,22624 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $513 | $12,95031 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 250 pulmonary disease providers in Arizona.
Other pulmonary disease in Phoenix
- Rajat WaliaPhoenix$748K
- Brian PorvinPhoenix$276K
- Abid KhokarPhoenix$262K
- Tony HodgesPhoenix$248K
- Mark GotfriedPhoenix$196K
- Rajeev SaggarPhoenix$161K
- Gregory AhearnPhoenix$144K
- Jagruti PatelPhoenix$141K
- Ali SaeedPhoenix$138K
- Ramit SharmaPhoenix$65K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.